Table 2.

Summary of past and current clinical trials targeting components of the TME

Trial statusOutcome
InterventionCurrent phaseTrial identifierStatusMedian survivalReference
Erlotinib + gemcitabineIIINCT00026338Completed6.24 vs. 5.91 mo6
Oxaliplatin + irinotecan + leucovorin + 5-FUII/IIINCT00112658Completed11.1 vs. 6.8 mo7
GDC-0449 + gemcitabineIINCT01064622Active
IPI-926 + gemcitabineI/IINCT01130142StoppedN/A
nab-Paclitaxel + gemcitabineI/IINCT00398086Completed12.2 mo48
PEGPH20 + gemcitabineI/IINCT01453153Active
Marimastat + gemcitabineIIIN/ACompleted5.44 vs. 5.39 mo65
Cilengitide + gemcitabineIIN/ACompleted6.7 vs. 7.7 mo66
BAY 12-9566IIIN/ACompleted3.7 vs. 6.6 mo67
Bevacizumab + gemcitabineIIINCT00088894Completed5.8 vs. 5.9 mo68
Bevacizumab + erlotinib + gemcitabineIIIN/ACompleted7.1 vs. 6.0 mo69
Bevacizumab + docetaxelIIN/ACompleted4.1 vs. 5.4 mo70
Radiotherapy + capecitabine + bevacizumab, bevacizumab + gemcitabineIINCT00114179Completed11.971
Axitinib + gemcitabineIIINCT00471146Completed8.5 vs. 8.3 mo72
Sorafenib + gemcitabineIIN/ACompleted4.0 mo73
RO4929097IINCT01232829Active
MK0752 + gemcitabineI/IINCT01098344Active
Irradiated allogeneic GM-CSF–secreting tumor vaccineIINCT00084383Completed24.8 mo101
MUC1 peptide-loaded dendritic cell vaccineI/IIN/ACompleted26 mo102
IpilimumabIINCT00112580CompletedN/A103
CP-870,893 + gemcitabineINCT00711191Completed7.4 mo104
Mechanistic studies
GDC-0449 + gemcitabine0NCT01195415Active
GDC-0449IINCT01096732Active
Preoperative pimonidazoleN/ANCT01248637Active